Fernández-Ruiz M, Kumar D, Humar A. Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation. Clin Transl Immunol. 2014;3(2):e12.
Winthrop KL, Novosad SA, Baddley JW, Calabrese L, Chiller T, Polgreen P, et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis. 2015;74(12):2107–16.
Azoulay E, Pickkers P, Soares M, Perner A, Rello J, Bauer P, et al. Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. Intensive Care Med. 2017;43:1808–19.
Novosad SA, Winthrop KL. Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;58(11):1587–98.
Ko Y, Jeong B-H, Park HY, Koh W-J, Suh GY, Chung MP, et al. Outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients. J Crit Care. 2014;29(3):356–61.
Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis Off Publ Infect Dis Soc Am. 2002;34(8):1098–107.
Festic E, Gajic O, Limper AH, Aksamit TR. Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest. 2005;128(2):573–9.
Monnet X, Vidal-Petiot E, Osman D, Hamzaoui O, Durrbach A, Goujard C, et al. Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care Lond Engl. 2008;12(1):R28.
Jensen BN, Lisse IM, Gerstoft J, Borgeskov S, Skinhøj P. Cellular profiles in bronchoalveolar lavage fluid of HIV-infected patients with pulmonary symptoms: relation to diagnosis and prognosis. AIDS Lond Engl. 1991;5(5):527–33.
Lee JY, Park HJ, Kim YK, Yu S, Chong YP, Kim S-H, et al. Cellular profiles of bronchoalveolar lavage fluid and their prognostic significance for non-HIV-infected patients with Pneumocystis jirovecii pneumonia. J Clin Microbiol. 2015;53(4):1310–6.
Kim T, Sung H, Chong YP, Kim SH, Choo EJ, Choi SH, et al. Low lymphocyte proportion in bronchoalveolar lavage fluid as a risk factor associated with the change from trimethoprim/sulfamethoxazole used as first-line treatment for Pneumocystis jirovecii pneumonia. Infect Chemother. 2018;50(2):110–9.
Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey OW, La Voie L. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. N Engl J Med. 1990;323(21):1444–50.
Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, Kemper C, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med. 1990;323(21):1451–7.
Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113(5):1215–24.
Delclaux C, Zahar JR, Amraoui G, Leleu G, Lebargy F, Brochard L, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin Infect Dis Off Publ Infect Dis Soc Am. 1999;29(3):670–2.
Zahar JR, Robin M, Azoulay E, Fieux F, Nitenberg G, Schlemmer B. Pneumocystis carinii pneumonia in critically ill patients with malignancy: a descriptive study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2002;35(8):929–34.
Limper AH, Offord KP, Smith TF, Martin WJ. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989;140(5):1204–9.
Azoulay E, Parrot A, Flahault A, Cesari D, Lecomte I, Roux P, et al. AIDS-related Pneumocystis carinii pneumonia in the era of adjunctive steroids: implication of BAL neutrophilia. Am J Respir Crit Care Med. 1999;160(2):493–9.
Wettstein RB, Shelledy DC, Peters JI. Delivered oxygen concentrations using low-flow and high-flow nasal cannulas. Respir Care. 2005;50(5):604–9.
ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526–33.
Iriart X, Witkowski B, Courtais C, Abbes S, Tkaczuk J, Courtade M, et al. Cellular and cytokine changes in the alveolar environment among immunocompromised patients during Pneumocystis jirovecii infection. Med Mycol. 2010;48(8):1075–87.
Limongi F, Fallahi P. Hypersensitivity pneumonitis and alpha-chemokines. Clin Ter. 2017;168(2):e140–5.
Kojicic M, Li G, Hanson AC, Lee K-M, Thakur L, Vedre J, et al. Risk factors for the development of acute lung injury in patients with infectious pneumonia. Crit Care Lond Engl. 2012;16(2):R46.
Boonsarngsuk V, Sirilak S, Kiatboonsri S. Acute respiratory failure due to Pneumocystis pneumonia: outcome and prognostic factors. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2009;13(1):59–66.
Kim SJ, Lee J, Cho Y-J, Park YS, Lee C-H, Yoon HI, et al. Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection. J Infect. 2014;69(1):88–95.
Lemiale V, Debrumetz A, Delannoy A, Alberti C, Azoulay E. Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia. Respir Res. 2013;14(1):87.
Roblot F, Le Moal G, Godet C, Hutin P, Texereau M, Boyer E, et al. Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study. J Infect. 2003;47(1):19–27.
Iriart X, Witkowski B, Cassaing S, Abbes S, Menard S, Fillaux J, et al. Alveolar and blood T lymphocyte profiles in Pneumocystis jirovecii-positive patients: effects of HIV status. J Infect Dis. 2011;204(4):544–53.
Azoulay E, Roux A, Vincent F, Kouatchet A, Argaud L, Rabbat A, et al. A multivariable prediction model for Pneumocystis jirovecii pneumonia in hematology patients with acute respiratory failure. Am J Respir Crit Care Med. 2018.
Lamia B, Hellot M-F, Girault C, Tamion F, Dachraoui F, Lenain P, et al. Changes in severity and organ failure scores as prognostic factors in onco-hematological malignancy patients admitted to the ICU. Intensive Care Med. 2006;32(10):1560–8.
Tokioka F, Okamoto H, Yamazaki A, Itou A, Ishida T. The prognostic performance of qSOFA for community-acquired pneumonia. J Intensive Care. 2018;6:46.
Capelozzi VL, Allen TC, Beasley MB, Cagle PT, Guinee D, Hariri LP, et al. Molecular and immune biomarkers in acute respiratory distress syndrome: a perspective from members of the pulmonary pathology society. Arch Pathol Lab Med. 2017;141(12):1719–27.
Dhanireddy S, Altemeier WA, Matute-Bello G, O’Mahony DS, Glenny RW, Martin TR, et al. Mechanical ventilation induces inflammation, lung injury, and extra-pulmonary organ dysfunction in experimental pneumonia. Lab Investig J Tech Methods Pathol. 2006;86(8):790–9.
Ruan S, Samuelson DR, Assouline B, Morre M, Shellito JE. Treatment with interleukin-7 restores host defense against pneumocystis in CD4+ T-lymphocyte-depleted mice. Infect Immun. 2015;84(1):108–19.
Matsumura Y, Ito Y, Yamamoto M, Matsushima A, Nagao M, Takakura S, et al. Pneumocystis polymerase chain reaction and blood (1 → 3)-β-d-glucan assays to predict survival with suspected Pneumocystis jirovecii pneumonia. J Infect Chemother. 2014;20(2):109–14.
Roblot F, Le Moal G, Kauffmann-Lacroix C, Bastides F, Boutoille D, Verdon R, et al. Pneumocystis jirovecii pneumonia in HIV-negative patients: a prospective study with focus on immunosuppressive drugs and markers of immune impairment. Scand J Infect Dis. 2014;46(3):210–4.
Roblot F, Imbert S, Godet C, Kauffmann C, Ragot S, Le Moal G, et al. Risk factors analysis for Pneumocystis jirovecii pneumonia (PCP) in patients with haematological malignancies and pneumonia. Scand J Infect Dis. 2004;36(11–12):848–54.
Roux A, Canet E, Valade S, Gangneux-Robert F, Hamane S, Lafabrie A, et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis. 2014;20(9):1490–7.
Torres HA, Chemaly RF, Storey R, Aguilera EA, Nogueras GM, Safdar A, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jirovecii pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2006;25(6):382–8.
Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H. Peripheral blood CD4+ T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest. 2000;118(3):712–20.
Martin-Garrido I, Carmona EM, Specks U, Limper AH. Pneumocystis pneumonia in patients treated with rituximab. Chest. 2013;144(1):258–65.
Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992;267(6):832–7.
Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis jirovecii pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015;4:CD006150.
Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183(1):96–128.
Kofteridis DP, Valachis A, Velegraki M, Antoniou M, Christofaki M, Vrentzos GE, et al. Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients. J Infect Chemother Off J Jpn Soc Chemother. 2014;20(7):412–6.
Bollée G, Sarfati C, Thiéry G, Bergeron A, de Miranda S, Menotti J, et al. Clinical picture of Pneumocystis jirovecii pneumonia in cancer patients. Chest. 2007;132(4):1305–10.
Roblot F, Godet C, Le Moal G, Garo B, Faouzi Souala M, Dary M, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2002;21(7):523–31.
Schmidt JJ, Lueck C, Ziesing S, Stoll M, Haller H, Gottlieb J, et al. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years. Crit Care Lond Engl. 2018;22(1):307.
Miller RF, Le Noury J, Corbett EL, Felton JM, De Cock KM. Pneumocystis carinii infection: current treatment and prevention. J Antimicrob Chemother. 1996;37(Suppl B):33–53.